Its Own Stars Said It Was ‘Cheesy.’ Now It’s a Monster Hit.
The New York Times
Despite the lack of big names or critical hype, the romance adaptation “Virgin River” has been one of Netflix’s biggest, most reliable successes.
Despite the lack of big names or critical hype, the romance adaptation “Virgin River” has been one of Netflix’s biggest, most reliable successes.
Scientists studied centuries-old bird feathers from an ancient tomb on the coast, and then traced the origins back to the Amazon.
Blaming chatbots, they are joining an earlier push for better protections by parents who say social media contributed to their children’s deaths.
The agency is proposing allowing other tastes for vapes, like mint, coffees, spices or tea, to appeal to adults. At the same time, illicit candy-flavored types aimed at teenagers have flooded the market.
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.
Researchers have devised a new tool for discerning between naturally occurring viral outbreaks and those resulting from lab accidents.
The artificial intelligence company filed two lawsuits against the Department of Defense, saying it was being punished on ideological grounds.
After outgrowing its original home, the National Museum of Mathematics has added new exhibits and an art gallery space in what was an empty storefront along the Avenue of the Americas in Manhattan.
The strawberry guava, one of the world’s worst invasive species, hinders forest restoration on the island while feeding its famous endangered primates.
New data about the DART spacecraft’s effects adds evidence that Earth could be defended from future deadly asteroids by diverting their orbits.
A new analysis of prescription data found that emergency room orders for acetaminophen for pregnant women fell for weeks after the federal warning.
The Antscan database captures the tiny insects’ diversity and shows how the world’s living things could be rendered in three dimensions.
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
Brian Janous, a former Microsoft executive, and his firm Cloverleaf have become modern-day land men, packaging electricity and land for data centers.